Enhancing Brain Cancer Treatment with Microbeam Radiation Therapy and Radiosensitisers
Author Information
Author(s): Valceski Michael, Engels Elette, Vogel Sarah, Paino Jason, Potter Dylan, Hollis Carolyn, Khochaiche Abass, Barnes Micah, O’Keefe Alice, Cameron Matthew, Roughley Kiarn, Rosenfeld Anatoly, Lerch Michael, Corde Stéphanie, Tehei Moeava
Primary Institution: University of Wollongong
Hypothesis
The use of radiosensitisers, such as IUdR+MTX and Tm+MTX, will result in improved cancer-killing due to local dose enhancement in 9LGS cells.
Conclusion
The study found that combining microbeam radiation therapy with radiosensitisers significantly enhances cancer cell-killing while sparing healthy tissue.
Supporting Evidence
- Microbeam radiation therapy (MRT) can spare normal tissues while maintaining tumor control.
- Combining MRT with radiosensitising nanoparticles and chemotherapeutic drugs enhances radiation damage.
- γH2AX imaging allows for accurate measurement of DNA damage and biological responses to MRT.
- The peak-to-valley dose ratio (PVDR) was accurately measured biologically using γH2AX imaging.
- Radiosensitisers like methotrexate and iododeoxyuridine significantly enhance cell-killing effects.
- High-Z nanoparticles broaden MRT peaks, increasing radiation dose to nearby cells.
- Radiosensitiser-enhanced MRT can improve treatment efficacy while reducing overall radiation exposure.
Takeaway
This study shows that special treatments can help kill brain cancer cells better while protecting healthy cells, making it safer for patients.
Methodology
An in vitro study was performed using γH2AX imaging and clonogenic cell survival assays to assess the effects of various radiosensitisers combined with microbeam radiation therapy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website